Subscribe
Bausch + Lomb has initiated its phase III clinical program of latanoprostene bunod (licensed by Nicox S.A.) for the reduction of IOP in glaucoma or ocular hypertension.
Judy E. Kim, MD, FARVO, FASRS; Anat Loewenstein, MD, MHA; Deepak Sambhara, MD, FASRS
September 13, 2026
September 26, 2026
SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS
Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO
Basil Williams, MD; Maura Di Nicola, MD
John Kitchens, MD; Michael W. Stewart, MD
Dilsher S. Dhoot, MD, FASRS
Deep Parikh, MD
Carl J. Danzig, MD, FASRS
Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO
Uday Devgan, MD, FACS, FRCS